Tumor-induced osteomalacia

Endocrine-Related Cancer

Volumn 18, Issue 3, 2011, Pages

  Chong, William H ^a   Molinolo, Alfredo A ^b   Chen, Clara C ^a   Collins, Michael T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; CINACALCET; CISPLATIN; DASATINIB; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 23; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; OCTREOTIDE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS; SODIUM PHOSPHATE COTRANSPORTER 2A; SODIUM PHOSPHATE COTRANSPORTER 2C; TECHNETIUM 99M; THALLIUM 201; VITAMIN D;

BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CANCER SURGERY; CELL PROLIFERATION; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; ELECTRON MICROSCOPY; GENETIC SCREENING; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPOPARATHYROIDISM; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; MIXED CONNECTIVE TISSUE DISEASE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENIC OSTEOMALACIA; OSTEOSARCOMA; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; REGULATORY MECHANISM; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL; ULTRASOUND; URINALYSIS;

ALGORITHMS; ANIMALS; DIAGNOSIS, DIFFERENTIAL; FIBROBLAST GROWTH FACTORS; HUMANS; NEOPLASMS; NEOPLASMS, CONNECTIVE TISSUE; OSTEOMALACIA; PHOSPHATES;

EID: 79960083752     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0006     Document Type: Review

References (224)

1. ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nature Genetics 26 345-348. (doi:10.1038/81664)
2. Ahn JM, Kim HJ, Cha CM, Kim J & Yim SG 2007 Oncogenic osteomalacia: induced by tumor, cured by surgery. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 103 636-641. (doi:10.1016/j.tripleo.2005.12. 027)
3. Albright F & Reifenstein E 1948 Clinical hyperparathyroidism. In Parathyroid Glands & Metabolic Bone Disease, ch 3, p 56. Baltimore, MD, USA: The Williams & Wilkins Company.
4. Albright F, Butler AM & Bloomber E 1937 Rickets resistant to vitamin D therapy. American Journal of Diseases of Children 54 529-547.
5. Alon U & Hellerstein S 1994 Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatric Nephrology 8 250-251. (doi:10.1007/BF00865491)
6. Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S & Quarles LD 2008 Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clinical Journal of the American Society of Nephrology 3 658-664. (doi:10.2215/CJN.04981107)
7. Andreopoulou P, Dumitrescu CE, Kelly MH, Brillante B, Cutler CM, Wodajo FM, Chang R & Collins MT 2010a Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. Journal of Bone and Mineral Research [in press]. (doi:10.1002/jbmr.316)
8. Andreopoulou P, Millo C, Reynolds J, Kelly M, Brillante B, Wodajo FM, Chang R, Chen CC & Collins MT 2010b Multimodality Diagnosis and Treatment of Tumor Induced Osteomalacia. Endocrine Reviews 31 (Supplement 1) OR08-6 S49.
9. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S et al. 2009 Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. Journal of Bone and Mineral Research 24 1879-1888. (doi:10.1359/jbmr.090509)
10. Aono Y, Hasegawa H, Yamazaki Y, Shimada T, Fujita T, Yamashita T & Fukumoto S 2010 Anti-FGF23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. Journal of Bone and Mineral Research 26 803-810. (doi:10.1002/jbmr.275)
11. Aranami F, Segawa H, Furutani J, Kuwahara S, Tominaga R, Hanabusa E, Tatsumi S, Kido S, Ito M & Miyamoto K 2010 Fibroblast growth factor 23 mediates the phosphaturic actions of cadmium. Journal of Medical Investigation 57 95-108. (doi:10.2152/jmi.57.95)
12. Auethavekiat P, Roberts JR, Biega TJ, Toney MO, Christensen RS, Belnap CM & Berenberg JL 2005 Case 3. Oncogenic osteomalacia associated with hemangiopericytoma localized by octreotide scan. Journal of Clinical Oncology 23 3626-3628. (doi:10.1200/JCO.2005.05.043)
13. Bahrami A, Weiss SW, Montgomery E, Horvai AE, Jin L, Inwards CY & Folpe AL 2009 RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. American Journal of Surgical Pathology 33 1348-1354. (doi:10.1097/PAS.0b013e3181aa2311)
14. Baroncelli GI, Angiolini M, Ninni E, Galli V, Saggese R & Giuca MR 2006 Prevalence and pathogenesis of dental and periodontal lesions in children with X-linked hypophosphatemic rickets. European Journal of Paediatric Dentistry 7 61-66.
15. Baronofsky SI, Kalbhen CL, Demos TC & Sizemore GW 1999 Oncogenic osteomalacia secondary to a hemangiopericytoma of the hip: case report. Canadian Association of Radiologists Journal 50 26-28. (Pubitemid 29162148)
16. Barth JH, Jones RG & Payne RB 2000 Calculation of renal tubular reabsorption of phosphate: the algorithm performs better than the nomogram. Annals of Clinical Biochemistry 37 79-81. (doi:10.1258/0004563001901371)
17. Beech TJ, Rokade A, Gittoes N & Johnson AP 2007 A haemangiopericytoma of the ethmoid sinus causing oncogenic osteomalacia: a case report and review of the literature. International Journal of Oral and Maxillofacial Surgery 36 956-958. (doi:10.1016/j.ijom.2007.03.005)
18. Benet-Pages A, Orlik P, Strom TM & Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Human Molecular Genetics 14 385-390. (doi:10.1093/hmg/ddi034)
19. Bergwitz C & Juppner H 2010 Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annual Review of Medicine 61 91-104. (doi:10.1146/annurev.med.051308.111339)
20. Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, Frappier D, Burkett K, Carpenter TO, Anderson D et al. 2006 SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. American Journal of Human Genetics 78 179-192. (doi:10.1086/499409)
21. van Boekel G, Ruinemans-Koerts J, Joosten F, Dijkhuizen P, van Sorge A & de Boer H 2008 Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. European Journal of Endocrinology 158 431-437. (doi:10.1530/EJE-07-0779)
22. Bonnardeaux A & Bichet D 2008 Inherited disorders associated with generalized dysfunction of the proximal tubule (renal Fanconi syndrome). In Brenner & Rectors: The Kidney, 8 edn, pp 1390-1399. Ed B Brenner. Philadelphia, PA: Saunders Elsevier.
23. Cai Q, Hodgson SF, Kao PC, Lennon VA, Klee GG, Zinsmiester AR & Kumar R 1994 Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. New England Journal of Medicine 330 1645-1649. (doi:10.1056/NEJM199406093302304)
24. Carey DE, Drezner MK, Hamdan JA, Mange M, Ahmad MS, Mubarak S & Nyhan WL 1986 Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: a variant of tumor-induced osteomalacia. Journal of Pediatrics 109 994-1000. (doi:10.1016/S0022-3476(86)80283-9)
25. 111In-pentetreotide total body scan. Clinical and Experimental Rheumatology 21 493-496.
26. Chadha V & Alon US 2009 Hereditary renal tubular disorders. Seminars in Nephrology 29 399-411. (doi:10.1016/j.semnephrol.2009.03.013)
27. Cheung FM, Ma L, Wu WC, Siu TH, Choi PT & Tai YP 2006 Oncogenic osteomalacia associated with an occult phosphaturic mesenchymal tumour: clinico-radiologicopathological correlation and ultrastructural studies. Hong Kong Medical Journal 12 319-321. (Pubitemid 44285149)
28. Chouhan V, Agrawal K, Vinothkumar TK & Mathesul A 2010 Bilateral insufficiency fracture of the femoral head and neck in a case of oncogenic osteomalacia. Journal of Bone and Joint Surgery. British Volume 92 1028-1031. (doi:10.1302/0301-620X.92B7.24526)
29. Clunie GP, Fox PE & Stamp TC 2000 Four cases of acquired hypophosphataemic ('oncogenic') osteomalacia. Problemsof diagnosis, treatment and long-termmanagement. Rheumatology 39 1415-1421. (doi:10.1093/rheumatology/ 39.12.1415)
30. Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P & Robey PG 2001 Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. Journal of Bone and Mineral Research 16 806-813. (doi:10.1359/jbmr.2001.16.5.806)
31. Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, Liu J, Fedarko NS & Winer KK 2005 Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D. Journal of Bone and Mineral Research 20 1944-1950. (doi:10.1359/JBMR.050718)
32. Colt E, Gopan T & Chong HS 2005 Oncogenic osteomalacia cured by removal of an organized hematoma. Endocrine Practice 11 190-193. (Pubitemid 41613908)
33. Dash T, Parker MG & Lafayette RA 1997 Profound hypophosphatemia and isolated hyperphosphaturia in two cases of multiple myeloma. American Journal of Kidney Diseases 29 445-448. (doi:10.1016/S0272-6386(97)90207-9)
34. Davis S, Kessler W, Haddad BM & Maesaka JK 1980 Acute renal tubular dysfunction following cis-dichlorodiammine platinum therapy. Journal of Medicine 11 133-141. (Pubitemid 10036619)
35. De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY et al. 2002 Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. Journal of Bone and Mineral Research 17 1102-1110. (doi:10.1359/jbmr.2002.17.6. 1102)
36. Dehghani M, Dabaghmanesh MH & Omrani GH 2010 Photoclinic. Oncogenic osteomalacia. Archives of Iranian Medicine 13 253-254.
37. Dent CE & Gertner JM 1976 Hypophosphataemic osteomalacia in fibrous dysplasia. Quarterly Journal of Medicine 45 411-420.
38. Dewitt CA, Collins MT & Cowen EW 2007 Diffuse pain, hypophosphatemia, and a subcutaneous nodule. Journal of the American Academy of Dermatology 57 509-512. (doi:10.1016/j.jaad.2007.05.010)
39. Dissanayake AM, Wilson JL, Holdaway IM & Reid IR 2003 Oncogenic osteomalacia: culprit tumour detection whole body magnetic resonance imaging. Internal Medicine Journal 33 615-616. (doi:10.1111/j.1445-5994.2003.00488.x)
40. Dowman JK & Khattak FH 2006 Oncogenic hypophosphataemic osteomalacia mimicking bone metastases on isotope bone scan. Annals of Rheumatic Disease 65 1664. (doi:10.1136/ard.2006.057943)
41. Drezner M 1999 Tumor-induced osteomalacia. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4 edn, Ed M Favus. Philadelphia, PA: Lippincott Williams & Wilkins
42. Drezner MK 2001 Tumor-induced osteomalacia. Reviews in Endocrine & Metabolic Disorders 2 175-186. (doi:10.1023/A:1010006811394)
43. Duet M, Kerkeni S, Sfar R, Bazille C, Liote F & Orcel P 2008 Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clinical Nuclear Medicine 33 752-756. (doi:10.1097/RLU. 0b013e31818866bf)
44. Dumitrescu CE, Kelly MH, Khosravi A, Hart TC, Brahim J, White KE, Farrow EG, Nathan MH, Murphey MD & Collins MT 2009 A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features. Osteoporosis International 20 1273-1278. (doi:10.1007/s00198-008-0775-z)
45. Dupond JL, Mahammedi H, Magy N, Blagosklonov O, Meaux-Ruault N & Kantelip B 2005a Detection of a mesenchymal tumor responsible for hypophosphatemic osteomalacia using FDG-PET. European Journal of Internal Medicine 16 445-446. (doi:10.1016/j.ejim.2005.07.003)
46. Dupond JL, Mahammedi H, Prie D, Collin F, Gil H, Blagosklonov O, Ricbourg B, Meaux-Ruault N & Kantelip B 2005b Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone 36 375-378. (doi:10.1016/j.bone.2005.01.001)
47. Earle KE, Seneviratne T, Shaker J & Shoback D 2004 Fanconi's syndrome in HIV + adults: report of three cases and literature review. Journal of Bone and Mineral Research 19 714-721. (doi:10.1359/jbmr.2004.19.5.714)
48. Econs MJ & Drezner MK 1994 Tumor-induced osteomalacia - unveiling a new hormone. New England Journal of Medicine 330 1679-1681. (doi:10.1056/ NEJM199406093302310)
49. Econs MJ & McEnery PT 1997 Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. Journal of Clinical Endocrinology and Metabolism 82 674-681. (doi:10.1210/jc.82.2.674)
50. Elston MS, Stewart IJ, Clifton-Bligh R & Conaglen JV 2007 A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: description of the biochemical response of FGF23 to octreotide therapy and surgery. Bone 40 236-241. (doi:10.1016/j.bone.2006.07.027)
51. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T et al. 2008 Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42 1235-1239. (doi:10.1016/j.bone.2008.02.014)
52. von Falck C, Rodt T, Rosenthal H, Langer F, Goesling T, Knapp WH & Galanski M 2008 (68)Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. European Journal of Nuclear Medicine and Molecular Imaging 35 1034. (doi:10.1007/s00259-008-0755-8)
53. Farrow EG, Davis SI, Summers LJ & White KE 2009 Initial FGF23-mediated signaling occurs in the distal convoluted tubule. Journal of the American Society of Nephrology 20 955-960. (doi:10.1681/ASN.2008070783)
54. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S et al. 2006 Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nature Genetics 38 1310-1315. (doi:10.1038/ng1905)
55. Ferrari SL, Bonjour JP & Rizzoli R 2005 Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. Journal of Clinical Endocrinology and Metabolism 90 1519-1524. (doi:10.1210/jc.2004-1039)
56. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T et al. 2004 Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. American Journal of Surgical Pathology 28 1-30. (doi:10.1097/00000478-200401000-00001)
57. Friedlaender MM, Wald H, Dranitzki-Elhalel M, Zajicek HK, Levi M & Popovtzer MM 2001 Vitamin D reduces renal NaPi-2 in PTH-infused rats: complexity of vitamin D action on renal P(i) handling. American Journal of Physiology. Renal Physiology 281 F428-F433.
58. Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, Richard G & Sprecher E 2005 Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. Journal of Molecular Medicine 83 33-38. (doi:10.1007/s00109-004-0610-8)
59. Fuentealba C, Pinto D, Ballesteros F, Pacheco D, Boettiger O, Soto N, Fernandez W, Gabler F, Gonzales G & Reginato AJ 2003 Oncogenic hypophosphatemic osteomalacia associated with a nasal hemangiopericytoma. Journal of Clinical Rheumatology 9 373-379. (doi:10.1097/01.rhu.0000101906. 15276.ed)
60. Fukumoto S, Takeuchi Y, Nagano A & Fujita T 1999 Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 25 375-377. (doi:10.1016/S8756-3282(99)00170-2)
61. Furco A, Roger M, Mouchet B, Richard O, Martinache X & Fur A 2002 Osteomalacia cured by surgery. European Journal of Internal Medicine 13 67-69. (doi:10.1016/S0953-6205(01)00196-0)
62. Garcia CA & Spencer RP 2002 Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clinical Nuclear Medicine 27 582-583. (doi:10.1097/00003072-200208000-00007)
63. Gascon A, Cobeta-Garcia JC, Iglesias E, Lazaro JM & Muniesa JA 1999 Oncogenic osteomalacia in a patient with a fibrocystic nodule of the breast. Nephrology, Dialysis, Transplantation 14 1561-1563. (doi:10.1093/ndt/14.6.1561)
64. Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS & Collins MT 2007 Cinacalcet in the management of tumor-induced osteomalacia. Journal of Bone and Mineral Research 22 931-937. (doi:10.1359/jbmr.070304)
65. Gershinsky M, Croitoru S, Dickstein G, Bardicef O, GelmanR & Barmeir E 2007 Imaging of oncogenic osteomalacia. Israel Medical Association Journal 9 566-567. (Pubitemid 47193391)
66. Gore MO, Welch BJ, Geng W, Kabbani W, Maalouf NM, Zerwekh JE, Moe OW & Sakhaee K 2009 Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis. Kidney International 76 342-347. (doi:10.1038/ki.2008.355)
67. Gupta A, Winer K, Econs MJ, Marx SJ & Collins MT 2004 FGF-23 is elevated by chronic hyperphosphatemia. Journal of Clinical Endocrinology and Metabolism 89 4489-4492. (doi:10.1210/jc.2004-0724)
68. Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA Jr, Gagel RF & Hoff AO 2008 Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocrine Practice 14 1108-1114.
69. Haeusler G, Freilinger M, Dominkus M, Egerbacher M, Amann G, Kolb A, Schlegel W, Raimann A & Staudenherz A 2010 Tumor-induced hypophosphatemic rickets in an adolescent boy - clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue. Journal of Clinical Endocrinology and Metabolism 95 4511-4517. (doi:10.1210/jc.2010-0543)
70. Halperin F, Anderson RJ & Mulder JE 2007 Tumor-induced osteomalacia: the importance of measuring serum phosphorus levels. Nature Clinical Practice. Endocrinology & Metabolism 3 721-725. (doi:10.1038/ncpendmet0639)
71. Hannan FM, Athanasou NA, Teh J, Gibbons CL, Shine B & Thakker RV 2008 Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1. European Journal of Endocrinology 158 265-271. (doi:10.1530/EJE-07- 0485)
72. Harbeck B, Schocklmann H, Seekamp A, Czech N & Monig H 2009 Tumor-induced osteomalacia: successful treatment by radio-guided tumor surgery. Journal of Clinical Rheumatology 15 31-34. (doi:10.1097/RHU.0b013e3181960483)
73. Harish S, Jurriaans E, Jan E, Sur M & Colterjohn N 2008 Giant cell tumour of soft tissue causing oncogenic osteomalacia: report demonstrating the use of octreotide scintigraphy in tumour localization. Clinical Radiology 63 101-107. (doi:10.1016/j.crad.2007.05.017)
74. Harvey JN, Gray C & Belchetz PE 1992 Oncogenous osteomalacia and malignancy. Clinical Endocrinology 37 379-382. (doi:10.1111/j.1365-2265.1992. tb02342.x)
75. Hasegawa T, Shimoda T, Yokoyama R, Beppu Y, Hirohashi S & Maeda S 1999 Intracortical osteoblastic osteosarcoma with oncogenic rickets. Skeletal Radiology 28 41-45. (doi:10.1007/s002560050470)
76. Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, Gratz KF & Bastian L 2007a Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. Journal of Bone and Mineral Research 22 158-162. (doi:10.1359/jbmr.060909)
77. Hesse E, Rosenthal H & Bastian L 2007b Radiofrequency ablation of a tumor causing oncogenic osteomalacia. New England Journal of Medicine 357 422-424. (doi:10.1056/NEJMc070347)
78. Heylen A, Dasnoy D, Hustin J & Pochet JM 1999 Tumor-related osteomalacia followed after treatment by hyperparathyroidism. Revue du Rhumatisme (English ed.) 66 53-57. (Pubitemid 29057132)
79. Hodgson SF, Clarke BL, Tebben PJ, Mullan BP, Cooney WP III & Shives TC 2006 Oncogenic osteomalacia: localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy. Endocrine Practice 12 35-42.
80. Ichikawa S, Sorenson AH, Imel EA, Friedman NE, Gertner JM & Econs MJ 2006 Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria. Journal of Clinical Endocrinology and Metabolism 91 4022-4027. (doi:10.1210/jc.2005-2840)
81. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A et al. 2006 Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. Journal of Clinical Endocrinology and Metabolism 91 2055-2061. (doi:10.1210/jc.2005-2105)
82. Imel EA, Hui SL & Econs MJ 2007 FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. Journal of Bone and Mineral Research 22 520-526. (doi:10.1359/jbmr.070107)
83. Inokuchi G, Tanimoto H, Ishida H, Sugimoto T, Yamauchi M, Miyauchi A & Nibu K 2006 A paranasal tumor associated with tumor-induced osteomalacia. Laryngoscope 116 1930-1933. (doi:10.1097/01.mlg.0000231295.67060.89)
84. Ishii A, Imanishi Y, Kobayashi K, Hashimoto J, Ueda T, Miyauchi A, Koyano HM, Kaji H, Saito T, Oba K et al. 2010 The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels. Calcified Tissue International 86 455-462. (doi:10.1007/s00223-010-9369-9)
85. Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T & Fujita T 2007 Effect of acute changes of serum phosphate on fibroblast growth factor (FGF) 23 levels in humans. Journal of Bone and Mineral Metabolism 25 419-422. (doi:10.1007/s00774-007-0779-3)
86. Ito N, Shimizu Y, Suzuki H, Saito T, Okamoto T, Hori M, Akahane M, Fukumoto S & Fujita T 2010 Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. Journal of Internal Medicine 268 390-394. (doi:10.1111/j.1365-2796.2010.02262.x)
87. Ivker R, Resnick SD & Skidmore RA 1997 Hypophosphatemic vitamin D-resistant rickets, precocious puberty, and the epidermal nevus syndrome. Archives of Dermatology 133 1557-1561. (doi:10.1001/archderm.133.12.1557)
88. Izzedine H, Launay-Vacher V, Isnard-Bagnis C & Deray G 2003 Drug-induced Fanconi's syndrome. American Journal of Kidney Diseases 41 292-309. (doi:10.1053/ajkd.2003.50037)
89. Jacob JJ, Finny P, Thomas M, Thomas N & John M 2007 Oncogenic osteomalacia. Journal of Association of Physicians of India 55 231-233.
90. Jagtap VS, Sarathi V, Lila AR, Malhotra G, Sankhe SS, Bandgar T, Menon P & Shah NS 2010 Tumor induced osteomalacia: a single center experience. Endocrine Practice 16 1-19. (doi:10.4158/10024.GL)
91. Jan de Beur SM 2005 Tumor-induced osteomalacia. Journal of the American Medical Association 294 1260-1267. (doi:10.1001/jama.294.10.1260)
92. Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, Onobrakpeya O, Raisz LG, Watts NB, Sharon M et al. 2002 Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359 761-763. (doi:10.1016/S0140-6736(02)07846-7)
93. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O et al. 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. New England Journal of Medicine 348 1656-1663. (doi:10.1056/NEJMoa020881)
94. Jung GH, Kim JD, Cho Y, Chung SH, Lee JH & Sohn KR 2010 A 9-month-old phosphaturic mesenchymal tumor mimicking the intractable rickets. Journal of Pediatric Orthopaedics. Part B/ European Paediatric Orthopaedic Society, Pediatric Orthopaedic Society of North America 19 127-132. (doi:10.1097/BPB. 0b013e32832f59cb)
95. Kaul M, Silverberg M, Dicarlo EF, Schneider R, Bass AR & Erkan D 2007 Tumor-induced osteomalacia. Clinical Rheumatology 26 1575-1579. (doi:10.1007/s10067-006-0468-y)
96. Kaylie DM, Jackson CG & Gardner EK 2006 Oncogenic osteomalacia caused by phosphaturic mesenchymal tumor of the temporal bone. Otolaryngology - Head and Neck Surgery 135 653-654. (doi:10.1016/j.otohns.2005.03.086)
97. Kenealy H, Holdaway I & Grey A 2008 Occult nasal sinus tumours causing oncogenic osteomalacia. European Journal of Internal Medicine 19 516-519. (doi:10.1016/j.ejim.2008.01.011)
98. Kenny AP & Glen AC 1973 Tests of phosphate reabsorption. Lancet 2 158. (doi:10.1016/S0140-6736(73)93112-7)
99. Khadgawat R, Singh Y, Kansara S, Tandon N, Bal C, Seith A & Kotwal P 2009 PET/CT localisation of a scapular haemangiopericytoma with tumour-induced osteomalacia. Singapore Medical Journal 50 e55-e57.
100. Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, Wodajo FM, Fedarko NS & Collins MT 2007 Determination of the elimination half-life of fibroblast growth factor-23. Journal of Clinical Endocrinology and Metabolism 92 2374-2377. (doi:10.1210/jc.2006-2865)
101. Kimizuka T, Ozaki Y & Sumi Y 2004 Usefulness of 201Tl and 99mTc MIBI scintigraphy in a case of oncogenic osteomalacia. Annals of Nuclear Medicine 18 63-67. (doi:10.1007/BF02985616)
102. Kobayashi K, Nakao K, Kawai K, Ito K, Hukumoto S, Asakage T, Oota S & Motoi R 2010 Tumor-induced osteomalacia originating from the temporal bone: a case report. Head & Neck [in press]. (doi:10.1002/hed.21355)
103. Konishi K, Nakamura M, Yamakawa H, Suzuki H, Saruta T, Hanaoka H & Davatchi F 1991 Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis. American Journal of the Medical Sciences 301 322-328. (doi:10.1097/00000441-199105000-00006)
104. Koriyama N, Nishimoto K, Kodama T, Nakazaki M, Kurono Y, Yoshida H & Tei C 2006 Oncogenic osteomalacia in a case with a maxillary sinus mesenchymal tumor. American Journal of the Medical Sciences 332 142-147. (doi:10.1097/00000441-200609000-00010)
105. Kurien R, Manipadam MT & Rupa V 2010 Oncogenic osteomalacia in a patient with an ethmoid sinus tumour. Journal of Laryngology and Otology 124 799-803. (doi:10.1017/S0022215109992313)
106. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW et al. 2006 Regulation of fibroblast growth factor-23 signaling by klotho. Journal of Biological Chemistry 281 6120-6123. (doi:10.1074/jbc.C500457200)
107. Ladha SS, Whitaker MD & Bosch EP 2006 Oncogenic osteomalacia: muscular weakness and multiple fractures. Neurology 67 364-365. (doi:10.1212/01.wnl.0000225057.56863.33)
108. Lamont EB, Cavaghan MK & Brockstein BE 1999 Oncogenic osteomalacia as a harbinger of recurrent osteosarcoma. Sarcoma 3 95-99. (doi:10.1080/ 13577149977712)
109. Larsson T, Nisbeth U, Ljunggren O, Juppner H & Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney International 64 2272-2279. (doi:10.1046/j.1523-1755.2003.00328.x)
110. Lee HK, Sung WW, Solodnik P & Shimshi M 1995 Bone scan in tumor-induced osteomalacia. Journal of Nuclear Medicine 36 247-249.
111. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J et al. 2010 Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. American Journal of Human Genetics 86 273-278. (doi:10.1016/j.ajhg.2010.01.010)
112. Lewiecki EM, Urig EJ Jr & Williams RC Jr 2008 Tumor-induced osteomalacia: lessons learned. Arthritis and Rheumatism 58 773-777. (doi:10.1002/art.23278)
113. Lichter-Konecki U, Broman KW, Blau EB & Konecki DS 2001 Genetic and physical mapping of the locus for autosomal dominant renal Fanconi syndrome, on chromosome 15q15.3. American Journal of Human Genetics 68 264-268. (doi:10.1086/316923)
114. Lloyd SE, Pearce SH, Fisher SE, Steinmeyer K, Schwappach B, Scheinman SJ, Harding B, Bolino A, Devoto M, Goodyer P et al. 1996 A common molecular basis for three inherited kidney stone diseases. Nature 379 445-449. (doi:10.1038/379445a0)
115. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH et al. 2006a DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nature Genetics 38 1248-1250. (doi:10.1038/ng1868)
116. Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, Gershoni-Baruch R, Albers N, Lichtner P, Schnabel D et al. 2006b Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. American Journal of Human Genetics 78 193-201. (doi:10.1086/499410)
117. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G & Strom TM 2010 Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. American Journal of Human Genetics 86 267-272. (doi:10.1016/j.ajhg.2010.01.006)
118. Lui CY, Khoo R, Law TC & Chong SF 2002 Case report. Tumour-induced osteomalacia in a patient with osseous haemangioma. Clinical Radiology 57 1125-1127. (doi:10.1053/crad.2002.1091)
119. Malabanan AO, Turner AK, Rosenberg IN & Holick MF 1998 Oncogenic osteomalacia: clinical presentation, densitometric findings, and response to therapy. Journal of Clinical Densitometry 1 77-80. (doi:10.1385/JCD:1:1:77)
120. Mannstadt M, Lorente C & Juppner H 2008 Rapid detection of intact FGF-23 in tumor tissue from patients with oncogenic osteomalacia. Clinical Chemistry 54 1252-1254. (doi:10.1373/clinchem.2007.102418)
121. Marshall AE, Martin SE, Agaram NP, Chen JH, Horn EM, Douglas-Akinwande AC & Hattab EM 2010 A 61-year-old woman with osteomalacia and a thoracic spine lesion. Brain Pathology 20 499-502. (doi:10.1111/j.1750-3639.2009.00360.x)
122. McCance R 1947 Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Quarterly Journal of Medicine 16 33-46.
123. Meyer RA Jr, Meyer MH & Gray RW 1989 Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. Journal of Bone and Mineral Research 4 493-500. (doi:10.1002/jbmr.5650040407)
124. Miyauchi A, Fukase M, Tsutsumi M & Fujita T 1988 Hemangiopericytoma- induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity. Journal of Clinical Endocrinology and Metabolism 67 46-53. (doi:10.1210/jcem-67- 1-46)
125. Moran M & Paul A 2002 Octreotide scanning in the detection of a mesenchymal tumour in the pubic symphysis causing hypophosphataemic osteomalacia. International Orthopaedics 26 61-62. (doi:10.1007/s00264-001-0318- 0)
126. Mori Y, Ogasawara T, Motoi T, Shimizu Y, Chikazu D, Tamura K, Fukumoto S & Takato T 2010 Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 109 e57-e63. (doi:10.1016/j.tripleo.2009.10.052)
127. Mount D & Yu A 2008 Phosphate transport. In Brenner & Rectors: The Kidney, 8 edn, pp 196-204. Ed B Brenner. Philadelphia, PA: Saunders Elsevier
128. Mussig K, Oksuz MO, Pfannenberg C, Adam P, Zustin J, Beckert S & Petersenn S 2009 Somatostatin receptor expression in an epitheloid hemangioma causing oncogenic osteomalacia. Journal of Clinical Endocrinology and Metabolism 94 4123-4124. (doi:10.1210/jc.2009-0927)
129. Nakahama H, Nakanishi T, Uno H, Takaoka T, Taji N, Uyama O, Kitada O, Sugita M, Miyauchi A, Sugishita T et al. 1995 Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urologia Internationalis 55 38-40. (doi:10.1159/000282746)
130. Narvaez J, Domingo-Domenech E, Narvaez JA, Nolla JM & Valverde J 2005 Acquired hypophosphatemic osteomalacia associated with multiple myeloma. Joint, Bone, Spine 72 424-426. (doi:10.1016/j.jbspin.2004.10.012)
131. Nasu T, Kurisu S, Matsuno S, Tatsumi K, Kakimoto T, Kobayashi M, Nakano Y, Wakasaki H, Furuta H, Nishi M et al. 2008 Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. Internal Medicine 47 957-961. (doi:10.2169/internalmedicine.47.0745)
132. Nawrot-Wawrzyniak K, Varga F, Nader A, Roschger P, Sieghart S, Zwettler E, Roetzer KM, Lang S, Weinkamer R, Klaushofer K et al. 2009 Effects of tumor-induced osteomalacia on the bone mineralization process. Calcified Tissue International 84 313-323. (doi:10.1007/s00223-009-9216-z)
133. Nayak A, Sharma SG, Tandon N & Ray R 2004 Phosphaturic mesenchymal tumor: a case report. Indian Journal of Pathology & Microbiology 47 530-533.
134. Nelson AE, Mason RS, Robinson BG, Hogan JJ, Martin EA, Ahlstrom H, Astrom G, Larsson T, Jonsson K, Wibell L et al. 2001 Diagnosis of a patient with oncogenic osteomalacia using a phosphate uptake bioassay of serum and magnetic resonance imaging. European Journal of Endocrinology 145 469-476. (doi:10.1530/eje.0.1450469)
135. Nelson AE, Bligh RC, Mirams M, Gill A, Au A, Clarkson A, Juppner H, Ruff S, Stalley P, Scolyer RA et al. 2003 Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. Journal of Clinical Endocrinology and Metabolism 88 4088-4094. (doi:10.1210/jc.2002-021919)
136. Nesbitt T, Coffman TM, Griffiths R & Drezner MK 1992 Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. Journal of Clinical Investigation 89 1453-1459. (doi:10.1172/JCI115735)
137. Nguyen BD 2006 Coexisting hyperparathyroidism and oncogenic osteomalacia: sestamibi and somatostatin receptor scintigraphy. Clinical Nuclear Medicine 31 648-651. (doi:10.1097/01.rlu.0000238192.37389.28)
138. Nguyen BD & Wang EA 1999 Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clinical Nuclear Medicine 24 130-131. (doi:10.1097/00003072-199902000-00016)
139. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H et al. 2006 Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney International 70 2141-2147. (doi:10.1038/sj.ki.5002000)
140. Nordstrom H, Lennquist S, Lindell B & Sjoberg HE 1977 Hypophosphataemia in severe burns. Acta Chirurgica Scandinavica 143 395-399.
141. Ogose A, Hotta T, Emura I, Hatano H, Inoue Y, Umezu H & Endo N 2001 Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiology 30 99-103. (doi:10.1007/s002560000306)
142. Ogura E, Kageyama K, Fukumoto S, Yagihashi N, Fukuda Y, Kikuchi T, Masuda M & Suda T 2008 Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23. Internal Medicine 47 637-641. (doi:10.2169/internalmedicine.47.0761)
143. Ohashi K, Ohnishi T, Ishikawa T, Tani H, Uesugi K & Takagi M 1999 Oncogenic osteomalacia presenting as bilateral stress fractures of the tibia. Skeletal Radiology 28 46-48. (doi:10.1007/s002560050471)
144. Oka M, Kamo T, Sasaki E, Kaji H, Nishizawa H, Imanishi Y & Nishigori C 2007 A case of phosphaturic mesenchymal tumour (mixed connective tissue variant) that developed in the subcutaneous tissue of a patient with oncogenic osteomalacia and produced fibroblast growth factor 23. British Journal of Dermatology 157 198-200. (doi:10.1111/j.1365-2133.2007.07940.x)
145. Omdahl JL & DeLuca HF 1971 Strontium induced rickets: metabolic basis. Science 174 949-951. (doi:10.1126/science.174.4012.949)
146. Oudet C, Martin-Coignard D, Pannetier S, Praud E, Champion G & Hanauer A 1997 A second family with XLRH displays the mutation S244L in the CLCN5 gene. Human Genetics 99 781-784. (doi:10.1007/s004390050448)
147. Paglia F, Dionisi S & Minisola S 2002 Octreotide for tumor-induced osteomalacia. New England Journal of Medicine 346 1748-1749 (author reply 1748-1749). (doi:10.1056/NEJM200205303462215)
148. Park JM, Woo YK, Kang MI, Kang CS & Hahn ST 2001 Oncogenic osteomalacia associated with soft tissue chondromyxoid fibroma. European Journal of Radiology 39 69-72. (doi:10.1016/S0720-048X(00)00279-5)
149. Payne RB 1998 Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Annals of Clinical Biochemistry 35 201-206. (Pubitemid 28127549)
150. Pedrazzoli M, Colletti G, Ferrari M, Rossetti G, Moneghini L & Autelitano L 2010 Mesenchymal phosphaturic neoplasm in the maxillary sinus: a case report. International Journal of Oral and Maxillofacial Surgery 39 1027-1032. (doi:10.1016/j.ijom.2010.04.039)
151. Peters KB, McLendon R, Morse MA & Vredenburgh JJ 2010 Treatment of recurrent intracranial hemangiopericytoma with SRC-related tyrosine kinase targeted therapy: a case report. Case Reports in Oncology 3 93-97. (doi:10.1159/000307468)
152. Peterson NR, Summerlin DJ & Cordes SR 2010 Multiple phosphaturic mesenchymal tumors associated with oncogenic osteomalacia: case report and review of the literature. Ear, Nose, & Throat Journal 89 E11-E15.
153. Pirola E, Vergani F, Casiraghi P, Leone EB, Guerra P & Sganzerla EP 2009 Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the thoracic spine. Journal of Neurosurgery. Spine 10 329-333. (doi:10.3171/2009.1. SPINE08351)
154. Policarpio-Nicolas ML, Abbott TE, Dalkin AC, Bennett-Wick J & Frierson HF Jr 2008 Phosphaturic mesenchymal tumor diagnosed by fine-needle aspiration and core biopsy: a case report and review of literature. Diagnostic Cytopathology 36 115-119. (doi:10.1002/dc.20772)
155. Pook MA, Wrong O, Wooding C, Norden AG, Feest TG & Thakker RV 1993 Dent's disease, a renal Fanconi syndrome with nephrocalcinosis and kidney stones, is associated with a microdeletion involving DXS255 and maps to Xp11.22. Human Molecular Genetics 2 2129-2134. (doi:10.1093/hmg/2.12.2129)
156. Prader A, Illig R, Uehlinger E & Stalder G 1959 Rickets following bone tumor. Helvetica Paediatrica Acta 14 554-565.
157. Radaideh AR, Jaradat D, Abu-Kalaf MM & Nusier MK 2009 Resolution of severe oncogenic hypophosphatemic osteomalacia after resection of a deeply located soft-tissue tumour. Current Oncology 16 87-90.
158. Rao DS, Parfitt AM, Villanueva AR, Dorman PJ & Kleerekoper M 1987 Hypophosphatemic osteomalacia and adult Fanconi syndrome due to light-chain nephropathy. Another form of oncogenous osteomalacia. American Journal of Medicine 82 333-338. (doi:10.1016/0002-9343(87)90081-7)
159. Ratanasuwan T, Chetsurakarn S, Ongphiphadhanakul B & Damrongkitchaiporn S 2008 A case report of tumor-induced osteomalacia: eight year followed-up. Journal of the Medical Association of Thailand 91 1900-1902.
160. Razzaque MS 2009 The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nature Reviews. Endocrinology 5 611-619. (doi:10.1038/nrendo.2009. 196)
161. Reese DM & Rosen PJ 1997 Oncogenic osteomalacia associated with prostate cancer. Journal of Urology 158 887. (doi:10.1016/S0022-5347(01)64351-9)
162. Reis-Filho JS, Paiva ME & Lopes JM 2002 Pathologic quiz case. A 36-year-old woman with muscle pain and weakness. Phosphaturic mesenchymal tumor (mixed connective tissue variant)/oncogenic osteomalacia. Archives of Pathology & Laboratory Medicine 126 1245-1246.
163. Reis-Filho JS, Paiva ME & Lopes JM 2004 August 2003: 47-year-old female with a 7-year history of osteomalacia and hypophosphatemia. Brain Pathology 14 111-112, 115.
164. Rendina D, De Filippo G, Tauchmanova L, Insabato L, Muscariello R, Gianfrancesco F, Esposito T, Cioffi M, Colao A, Strazzullo P et al. 2009 Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases. Calcified Tissue International 85 293-300. (doi:10.1007/s00223-009-9275-1)
165. Renkema KY, Alexander RT, Bindels RJ & Hoenderop JG 2008 Calcium and phosphate homeostasis: concerted interplay of new regulators. Annals of Medicine 40 82-91. (doi:10.1080/07853890701689645)
166. Rhee Y, Lee JD, Shin KH, Lee HC, Huh KB & Lim SK 2001 Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clinical Endocrinology 54 551-554. (doi:10.1046/j.1365- 2265.2001.01056.x)
167. Rico H, Fernandez-Miranda E, Sanz J, Gomez-Castresana F, Escriba A, Hernandez ER & Krsnik I 1986 Oncogenous osteomalacia: a new case secondary to a malignant tumor. Bone 7 325-329. (doi:10.1016/8756-3282(86)90251-6)
168. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ et al. 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. Journal of Clinical Investigation 112 683-692. (doi:10.1172/JCI18399)
169. Roarke MC & Nguyen BD 2007 PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clinical Nuclear Medicine 32 300-301. (doi:10.1097/01.rlu.0000257180.03964.51)
170. Romualdo-Silva DD, Silva BC, Caetano CV, Tiburcio AM, Nunes MB, Chagas SA, Polito ET, Ferreira AR & Purisch S 2009 Tumor-induced osteomalacia: a case report. Arquivos Brasileiros de Endocrinologia e Metabologia 53 378-382. (doi:10.1590/S0004-27302009000300014)
171. Sahnoune I, Tazi-Mezalek Z, Essaadouni L, Harmouche H, Ismael F, Adnaoui M, Aouni M, Kettani F & Maaouni A 2006 Oncogenic osteomalacia in a patient with hemangioma: a clinical diagnosis. Joint, Bone, Spine 73 115-118. (doi:10.1016/j.jbspin.2005.06.001)
172. Sakamoto A, Oda Y, Nagayoshi Y, Iwakiri K, Tamiya S, Iwamoto Y & Tsuneyoshi M 2001 Glomangiopericytoma causing oncogenic osteomalacia. A case report with immunohistochemical analysis. Archives of Orthopaedic and Trauma Surgery 121 104-108. (doi:10.1007/s004020000187)
173. Santer R, Schneppenheim R, Dombrowski A, Gotze H, Steinmann B & Schaub J 1997 Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nature Genetics 17 324-326. (doi:10.1038/ng1197-324)
174. Sato K, Obara T, Yamazaki K, Kanbe M, Nakajima K, Yamada A, Yanagisawa T, Kato Y, Nishikawa T & Takano K 2001 Somatic mutations of the MEN1 gene and microsatellite instability in a case of tertiary hyperparathyroidism occurring during high phosphate therapy for acquired, hypophosphatemic osteomalacia. Journal of Clinical Endocrinology and Metabolism 86 5564-5571. (doi:10.1210/jc.86.11.5564)
175. Savage CR & Zimmer LA 2009 Oncogenic osteomalacia from pterygopalatine fossa mass. Journal of Laryngology and Otology 123 1052-1054. (doi:10.1017/S0022215109004927)
176. Saville PD, Nassim JR, Stevenson FH, Mulligan L & Carey M 1955 Osteomalacia in Von Recklinghausen's neurofibromatosis; metabolic study of a case. BMJ 1 1311-1313. (doi:10.1136/bmj.1.4925.1311)
177. Scheinman SJ 1998 X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. Kidney International 53 3-17. (doi:10.1046/j.1523-1755.1998.00718.x)
178. Sciubba DM, Petteys RJ, Shakur SF, Gokaslan ZL, McCarthy EF, Collins MT, McGirt MJ, Hsieh PC, Nelson CS & Wolinsky JP 2009 En bloc spondylectomy for treatment of tumor-induced osteomalacia. Journal of Neurosurgery. Spine 11 600-604. (doi:10.3171/2009.6.SPINE08120)
179. Seijas R, Ares O, Sierra J & Perez-Dominguez M 2009 Oncogenic osteomalacia: two case reports with surprisingly different outcomes. Archives of Orthopaedic and Trauma Surgery 129 533-539. (doi:10.1007/s00402-008-0808-2)
180. Seufert J, Ebert K, Muller J, Eulert J, Hendrich C, Werner E, Schuuze N, Schulz G, Kenn W, Richtmann H et al. 2001 Octreotide therapy for tumor-induced osteomalacia. New England Journal of Medicine 345 1883-1888. (doi:10.1056/NEJMoa010839)
181. Sharkis DH, Devereux JP, Chako AC & Estep HL 1997 Reversible avascular necrosis of the femoral head in tumor-induced osteomalacia. Endocrine Practice 3 137-139.
182. Shelekhova KV, Kazakov DV, Hes O, Treska V & Michal M 2006 Phosphaturic mesenchymal tumor (mixed connective tissue variant): a case report with spectral analysis. Virchows Archiv 448 232-235. (doi:10.1007/s00428-005- 0149-2)
183. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S & Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Journal of Bone and Mineral Research 19 429-435. (doi:10.1359/JBMR.0301264)
184. Sommer S, Berndt T, Craig T & Kumar R 2007 The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. Journal of Steroid Biochemistry and Molecular Biology 103 497-503. (doi:10.1016/j.jsbmb.2006.11. 010)
185. Stark H, Eisenstein B, Tieder M, Rachmel A & Alpert G 1986 Direct measurement of TP/GFR: a simple and reliable parameter of renal phosphate handling. Nephron 44 125-128. (doi:10.1159/000184216)
186. Stone MD, Quincey C & Hosking DJ 1992 A neuroendocrine cause of oncogenic osteomalacia. Journal of Pathology 167 181-185. (doi:10.1002/path. 1711670204)
187. Szumera-Cieckiewicz A, Ptaszynski K, Pawelas A & Rutkowski P 2009 Oncogenic osteomalacia associated with phosphaturic mesenchymal tumour, mixed connective tissue type of the knee. Polish Journal of Pathology 60 193-198.
188. 3. Identification of a vitamin D-responsive element in the human NAPi-3 gene. Journal of Biological Chemistry 273 14575-14581. (doi:10.1074/jbc.273.23.14575)
189. Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K et al. 2004 Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. Journal of Clinical Endocrinology and Metabolism 89 3979-3982. (doi:10.1210/jc.2004-0406)
190. Tartaglia F, Minisola S, Sgueglia M, Blasi S, Brunelli D, Degli Effetti E, Maturo A, Cola A, Custureri F & Campana FP 2006 Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: a case report. Il Giornale di Chirurgia 27 9-13.
191. Taylor HC, Fallon MD & Velasco ME 1984 Oncogenic osteomalacia and inappropriate antidiuretic hormone secretion due to oat-cell carcinoma. Annals of Internal Medicine 101 786-788. (Pubitemid 15187369)
192. Teasell RW & Shapiro AP 2002 Misdiagnosis of conversion disorders. American Journal of Physical Medicine & Rehabilitation 81 236-240. (doi:10.1097/00002060-200203000-00015)
193. Terek R & Nielsen G 2001 Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-2001. A 14-year-old with abnormal bones and a sacral mass. New England Journal of Medicine 345 903-908. (doi:10.1056/NEJMcpc010029)
194. The HYP Consortium 1995 A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nature Genetics 11 130-136. (doi:10.1038/ng1095-130)
195. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V et al. 2004 Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nature Genetics 36 579-581. (doi:10.1038/ng1358)
196. Toyosawa S, Tomita Y, Kishino M, Hashimoto J, Ueda T, Tsujimura T, Aozasa K, Ijuhin N & Komori T 2004 Expression of dentin matrix protein 1 in tumors causing oncogenic osteomalacia. Modern Pathology 17 573-578. (doi:10.1038/modpathol.3800084)
197. Umphrey LG, Whitaker MD, Bosch EP & Cook CB 2007 Clinical and bone density outcomes of tumor-induced osteomalacia after treatment. Endocrine Practice 13 458-462.
198. Ungari C, Rocchi G, Rinna C, Agrillo A, Lattanzi A & Pagnoni M 2004 Hypophosphaturic mesenchymal tumor of the ethmoid associated with oncogenic osteomalacia. Journal of Craniofacial Surgery 15 523-527. (doi:10.1097/00001665- 200405000-00036)
199. Uramoto N, Furukawa M & Yoshizaki T 2009 Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris, Nasus, Larynx 36 104-105. (doi:10.1016/j.anl.2008.01.003)
200. 18F fluorodeoxyglucose uptake of a vertebral hemangioma responsible for oncogenic osteomalacia. European Journal of Internal Medicine 17 223. (doi:10.1016/j.ejim.2005.11.008)
201. Vollbrecht JE & Rao DS 2008 Images in clinical medicine. Tumor-induced osteomalacia. New England Journal of Medicine 358 1282. (doi:10.1056/NEJMicm066066)
202. Walton RJ & Bijvoet OL 1975 Nomogram for derivation of renal threshold phosphate concentration. Lancet 2 309-310. (doi:10.1016/S0140-6736(75) 92736-1)
203. Ward LM, Rauch F, White KE, Filler G, Matzinger MA, Letts M, Travers R, Econs MJ & Glorieux FH 2004 Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. Bone 34 905-911. (doi:10.1016/j.bone.2003.12.025)
204. Weidner N 1991 Review and update: oncogenic osteomalaciarickets. Ultrastructural Pathology 15 317-333. (doi:10.3109/01913129109016242)
205. Weidner N, Bar RS, Weiss D & Strottmann MP 1985 Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer 55 1691-1705. (doi:10.1002/1097- 0142(19850415)55:8〈1691::AID-CNCR2820550814〉3.0.CO;2-S)
206. Westerberg PA, Olauson H, Toss G, Wikstrom B, Morales O, Linde T, Jonsson K, Ljunggren O & Larsson TE 2008 Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia. Endocrine Practice 14 362-367.
207. White K, Evans W, O'Riordan JL, Speer M, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T & Strom T 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genetics 26 345-348. (doi:10.1038/81664)
208. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O et al. 2001 The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. Journal of Clinical Endocrinology and Metabolism 86 497-500. (doi:10.1210/jc.86.2.497)
209. White KE, Larsson TE & Econs MJ 2006 The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocrine Reviews 27 221-241. (doi:10.1210/er.2005-0019)
210. Wild D, Schmitt J, Ginj M, Macke H, Bernard B, Krenning E, De Jong M, Wenger S & Reubi J 2003 DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 fo labelling with various radiometals. European Journal of Nuclear Medicine and Molecular Imaging 30 1338-1347. (doi:10.1007/s00259-003-1255-5)
211. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. European Journal of Nuclear Medicine and Molecular Imaging 32 724. (doi:10.1007/s00259-004-1697- 4)
212. Wilkins GE, Granleese S, Hegele RG, Holden J, Anderson DW & Bondy GP 1995 Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. Journal of Clinical Endocrinology and Metabolism 80 1628-1634. (doi:10.1210/jc.80.5. 1628)
213. Williams K, Flanagan A, Folpe A, Thakker R & Athanasou NA 2007 Lymphatic vessels are present in phosphaturic mesenchymal tumours. Virchows Archiv 451 871-875. (doi:10.1007/s00428-007-0471-y)
214. Woo VL, Landesberg R, Imel EA, Singer SR, Folpe AL, Econs MJ, Kim T, Harik LR & Jacobs TP 2009 Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: report of a case and review of the literature. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 108 925-932. (doi:10.1016/j.tripleo.2009.07.005)
215. Woznowski M, Quack I, Stegbauer J, Buchner N, Rump LC & Schieren G 2008 Oncogenic osteomalacia, a rare paraneoplastic syndrome due to phosphate wasting - a case report and review of the literature. Clinical Nephrology 70 431-438.
216. Wyman AL, Paradinas FJ & Daly JR 1977 Hypophosphataemic osteomalacia associated with a malignant tumour of the tibia: report of a case. Journal of Clinical Pathology 30 328-335. (doi:10.1136/jcp.30.4.328)
217. Xia WB, Jiang Y, Li M, Xing XP, Wang O, Hu YY, Zhang HB, Liu HC, Meng XW & Zhou XY 2010 Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia. Chinese Medical Journal 123 1158-1162.
218. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T et al. 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. Journal of Clinical Endocrinology and Metabolism 87 4957-4960. (doi:10.1210/jc.2002-021105)
219. Yang IM, Park YK, Hyun YJ, Kim DY, Woo JT, Kim SW, Kim JW, Kim YS & Choi YK 1997 Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the oral cavity: a case report. Korean Journal of Internal Medicine 12 89-95.
220. Yavropoulou MP, Kotsa K, Gotzamani Psarrakou A, Papazisi A, Tranga T, Ventis S & Yovos JG 2010 Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. Hormones 9 274-278.
221. Yoshioka K, Nagata R, Ueda M, Yamaguchi T, Konishi Y, Hosoi M, Inoue T, Yamanaka K, Iwai Y & Sato T 2006 Phosphaturic mesenchymal tumor with symptoms related to osteomalacia that appeared one year after tumorectomy. Internal Medicine 45 1157-1160. (doi:10.2169/internalmedicine.45.1797)
222. Yun KI, Kim DH & Pyo SW 2009 A phosphaturic mesenchymal tumor of the floor of the mouth with oncogenic osteomalacia: report of a case. Journal of Oral and Maxillofacial Surgery 67 402-405. (doi:10.1016/j.joms.2008.01.007)
223. Zimering MB, Caldarella FA, White KE & Econs MJ 2005 Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes. Endocrine Practice 11 108-114. (Pubitemid 40668265)
224. Zura RD, Minasi JS & Kahler DM 1999 Tumor-induced osteomalacia and symptomatic looser zones secondary to mesenchymal chondrosarcoma. Journal of Surgical Oncology 71 58-62. (doi:10.1002/(SICI)1096-9098(199905)71:1〈58:: AID-JSO12〉3.0.CO;2-F)